- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02003508
Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination (Impress)
March 4, 2020 updated by: Marcus Chen, The Alfred
This study will examine how common HPV infection is in teenage males in Australia before and after the introduction of universal school based vaccination of males in Australia.
Study Overview
Status
Completed
Conditions
Detailed Description
Males aged 17 to 19 in Australia will be recruited from 2014.
Men will undergo sampling from the penis for HPV.
The prevalence of HPV infection will be determined in 2014-2015 and compared to the prevalence in 2016-2017.
Study Type
Observational
Enrollment (Actual)
345
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3053
- Melbourne Sexual Health Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Males aged 17-19 recruited from sexual health clinics and community sources
Description
Inclusion Criteria:
- Male
- Aged 17 to 19
- Able to complete study requirements
- Residing in Australia from 12 years of age
Exclusion Criteria:
-Males reporting sex with males in the past 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Pre-school based vaccination program (not vaccine eligible)
Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
|
|
Post-school based vaccination program (vaccine eligible)
Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of Penile HPV Genotypes
Time Frame: Single study visit (one time point per participant)
|
Prevalence of penile HPV genotypes among heterosexually active young men. Percentage of participants with specific genotypes on penile samples, as detected by Linear Array. Participants provided a single penile sample. |
Single study visit (one time point per participant)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Marcus Y Chen, PhD, Melbourne Sexual Health Centre Alfred Health and Central Clinical School Monash University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
December 29, 2017
Study Completion (Actual)
December 29, 2017
Study Registration Dates
First Submitted
December 2, 2013
First Submitted That Met QC Criteria
December 2, 2013
First Posted (Estimate)
December 6, 2013
Study Record Updates
Last Update Posted (Actual)
March 6, 2020
Last Update Submitted That Met QC Criteria
March 4, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IISP50939
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papillomavirus
-
H. Lee Moffitt Cancer Center and Research InstituteMerck Sharp & Dohme LLCCompleted
-
Laval UniversityCompletedHuman PapillomavirusCanada
-
University Hospital, ToulouseCompleted
-
University of North Carolina, Chapel HillHarvard Medical School (HMS and HSDM); Pfizer; North Carolina Department of Health...CompletedHuman PapillomavirusUnited States
-
M.D. Anderson Cancer CenterRecruitingHuman PapillomavirusUnited States
-
Kaiser PermanenteNational Cancer Institute (NCI)Recruiting
-
Université de Reims Champagne-ArdenneCompletedHuman PapillomavirusFrance
-
Queen Mary University of LondonCompleted
-
Lake Cumberland District Health DepartmentMerck Sharp & Dohme LLCCompletedHuman PapillomavirusUnited States
-
The University of Hong KongQueen Mary Hospital, Hong KongUnknown